Design Therapeutics Market Sentiment

Design Therapeutics Inc

DSGNNASDAQ

$10.21

0.545.58%

Last update: Nov 6, 4:00 PM

Earnings: Q3 2026 Earnings in 9 days from now on Tue Nov 17th, after the market close

Market sentiment signals for Design Therapeutics (DSGN): analyst consensus, short interest, options flow and insider activity.

Analyst Consensus— Outperform

Short Interest▼ 14.1% short float

Options Flow— N/A

Insider Activity— N/A

Analyst Consensus

Outperform

8 analysts

Options Flow (P/C)

—

Avg Consensus PT

$16

+59.2%

Highest Price Target

$26

+154.7%

Wells Fargo

Lowest Price Target

-51.0%

Wedbush

Short Interest

14.1%

Rising — Bearish

Insider Activity (30d)

—

Short Interest — % of Float

Date	Firm	Analyst & Accuracy	Upside / Downside	PT Change	Action	Rating
Nov 5, 2026	RBC Capital	Leonid Timashev—	+86.1%	$20 → $19	Maintained	Outperform
Oct 2, 2026	Wells Fargo	Tianqi Hang—	+154.7%	$26	Initiate	Overweight
May 4, 2026	Oppenheimer	Kostas Biliouris—	+105.7%	$18 → $21	Maintained	Outperform
Mar 16, 2026	Jefferies	Faisal Khurshid—	+46.9%	$15	Initiate	Buy
Mar 10, 2026	RBC Capital	Leonid Timashev—	+37.1%	$13 → $14	Maintained	Outperform
Jan 7, 2026	Oppenheimer	Trevor Allred—	+76.3%	$18	Initiate	Outperform
Dec 3, 2025	Leerink Partners	Joseph Schwartz—	+37.1%	$7 → $14	Upgrade	Market Perform→Outperform
Nov 20, 2025	RBC Capital	Leonid Timashev—	+27.3%	$6 → $13	Upgrade	Sector Perform→Outperform
Nov 6, 2025	RBC Capital	Leonid Timashev—	-41.2%	$5 → $6	Maintained	Sector Perform
Aug 6, 2024	RBC Capital	Leonid Timashev—	-60.8%	$4 → $4	Maintained	Sector Perform
May 7, 2024	Piper Sandler	Yasmeen Rahimi—	+17.5%	$6 → $12	Upgrade	Neutral→Overweight
Mar 20, 2024	RBC Capital	Leonid Timashev—	-60.8%	$4 → $4	Maintained	Sector Perform
Mar 20, 2024	Wedbush	Laura Chico—	-51.0%	$5	Maintained	Neutral
Nov 14, 2023	RBC Capital	Leonid Timashev—	-60.8%	$7 → $4	Maintained	Sector Perform